Related Experiment Videos
Hyperparathyroidism in the maintenance dialysis patient
Surgery, Gynecology & Obstetrics
|March 11, 1976
Summary
Secondary hyperparathyroidism is a significant issue in end-stage renal failure patients on dialysis, even with phosphate control. Progressive bone disease and high parathormone levels indicate this condition, which worsens with longer dialysis duration.
Area of Science:
- Nephrology
- Endocrinology
- Bone Metabolism
Background:
- Secondary hyperparathyroidism is a complication of end-stage renal failure (ESRF).
- Hyperphosphatemia is a key component of secondary hyperparathyroidism in ESRF.
- Home dialysis programs have been used to manage ESRF patients since 1968.
Purpose of the Study:
- To investigate the incidence and indicators of progressive hyperparathyroidism in ESRF patients undergoing home dialysis.
- To evaluate the effectiveness of subtotal parathyroidectomy in managing hyperparathyroidism-related bone disease.
Main Methods:
- Retrospective analysis of 101 ESRF patients in a home dialysis program (1968-present).
- Monitoring of serum phosphate, calcium, and parathormone levels.
- Assessment of bone disease progression and outcomes after subtotal parathyroidectomy.
Main Results:
- One-fourth of patients developed progressive hyperparathyroidism despite serum phosphate < 5 mg/dL.
- Hyperparathyroidism incidence increased with dialysis duration and was higher with parathormone levels > 500 pg/mL.
- Subtotal parathyroidectomy in 16 patients with large hyperplastic glands led to progressive bone disease improvement within six months.
Conclusions:
- Hyperparathyroidism remains a significant problem in dialysis patients, irrespective of phosphate control.
- Progressive bone disease and elevated parathormone levels are critical indicators of hyperparathyroidism in ESRF.
- Subtotal parathyroidectomy is an effective treatment for reversing bone disease associated with hyperparathyroidism in ESRF patients.